Elgharably Ahmed, Gomaa Asmaa I, Crossey Mary Me, Norsworthy Peter J, Waked Imam, Taylor-Robinson Simon D
Division of Digestive Health, Department of Surgery and Cancer, St Mary's Hospital, Imperial College London, London, UK; National Liver Institute, Menoufiya University, Shebeen El Kom, Egypt.
National Liver Institute, Menoufiya University, Shebeen El Kom, Egypt.
Int J Gen Med. 2016 Dec 20;10:1-6. doi: 10.2147/IJGM.S119301. eCollection 2017.
Hepatitis C viral infection is endemic in Egypt with the highest prevalence rate in the world. It is widely accepted that the implementation of mass population antischistosomal treatment involving administration of tartar emetic injections (from 1950s to 1980s) led to widespread infection. What is less well known, however, is that these schemes were implemented by the Egyptian Ministry of Health on the advice of the World Health Organization. There has been a spectrum of treatments to target the public health disaster represented by the hepatitis C problem in Egypt: from the use of PEGylated interferon to the recent use of direct acting antiviral drugs. Some new treatments have shown >90% efficacy. However, cost is a key barrier to access these new medicines. This is coupled with a growing population, limited resources, and a lack of infection control practices which means Egypt still faces significant disease control issues today.
丙型肝炎病毒感染在埃及呈地方性流行，其患病率为全球最高。人们普遍认为，20世纪50年代至80年代实施的大规模人群抗血吸虫治疗（涉及注射吐酒石）导致了广泛感染。然而，鲜为人知的是，这些计划是埃及卫生部根据世界卫生组织的建议实施的。针对埃及丙型肝炎问题所代表的公共卫生灾难，已有一系列治疗方法：从使用聚乙二醇化干扰素到最近使用直接作用抗病毒药物。一些新疗法已显示出超过90%的疗效。然而，成本是获取这些新药的关键障碍。再加上人口不断增长、资源有限以及缺乏感染控制措施，这意味着埃及如今仍面临重大的疾病控制问题。
